Podcast: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer

Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now.

STATEMENT OF NEED

Squamous cell lung carcinoma is a distinct histologic subtype of non–small cell lung cancer (NSCLC) that accounts for approximately 25% to 30% of all NSCLC cases and is associated with approximately 30% shorter survival compared with other subtypes of the disease. Because alterations and mutations for which targeted therapies are approved are uncommon in squamous cell NSCLC, treatment remains challenging. In addition, unique clinicopathologic characteristics and patient factors such as older age, advanced disease at diagnosis, and a higher incidence of comorbidities complicate effective treatment planning for patients with metastatic disease (Socinski et al, 2018). Therefore, it is essential that members of the multidisciplinary team maintain a comprehensive understanding of the efficacy and safety profiles of emerging therapies in order to inform treatment selection and adverse event management. In this activity, Mark G. Kris, MD, and Victoria Sherry, DNP, CRNP, AOCNP®, will update clinicians on strategies for developing personalized management plans to optimize the treatment and survivorship of patients with metastatic squamous cell NSCLC.

TARGET AUDIENCE

Oncologists, pulmonologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to
Assess patient and tumor characteristics that can inform individualized management plans in metastatic NSCLC
Distinguish emerging efficacy and safety data on novel cytotoxic therapies, immunotherapies, and monoclonal antibodies for metastatic squamous NSCLC
Appraise strategies to control treatment-related adverse events and optimize survivorship in patients with metastatic squamous NSCLC